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Key points 
 During the last 20 months, several case studies/series and randomised controlled trials of non-
invasive brain stimulation, deep brain stimulation, and neurofeedback in different eating 
disorders, obesity or food craving have appeared, with largely promising results. 
 Ongoing trials in eating disorders and obesity will increase the evidence base for 
neuromodulation and neurofeedback procedures and help establish the validity of treatment 
protocols. 
 Combining neuroimaging and neuromodulation techniques may help to identify distinct neural 
endophenotypes associated with differential intervention responses and may shed light on 
illness mechanisms. 
 Much still needs to be learnt about patient selection, intervention parameters, treatment targets 
and how to optimise protocols.  
 
2  
Abstract 
 
Purpose of review: Psychological interventions are the treatment of choice for most eating disorders 
(EDs), however, significant proportions of patients do not recover with these. Advances in 
understanding of the neurobiology of EDs have led to the development of targeted treatments, such as 
deep brain stimulation (DBS), non-invasive neuromodulation (NIBS) and neurofeedback. We review 
the emerging clinical evidence for the use of these interventions in EDs and obesity, together with their 
theoretical rationale. Finally, we reflect on future developments.  
Recent findings: During the last 20 months, seven case studies/series and seven randomised controlled 
trials (RCTs) of NIBS or neurofeedback in different EDs, obesity or food craving have appeared. These 
have largely had promising results. One NIBS trial, using a multi-session protocol, was negative. A case 
series of sub-callosal DBS in anorexia nervosa has also shown promise. A search of trial registries 
identified a further 21 neuromodulation/feedback studies in progress, indicating that this is an area of 
growing interest.  
Summary: At present neuromodulation and neurofeedback are largely experimental interventions; 
however, growing understanding of the mechanisms involved, together with the rising number of 
studies in this area means that the clinical utility of these interventions is likely to become clearer soon.  
Key words: eating disorders, obesity, neuromodulation, neurofeedback 
 
  
 
3  
Introduction  
Neuromodulation has been defined as use of “advanced medical device technologies to enhance or 
suppress activity of the nervous system for the treatment of disease. These technologies include 
implantable as well as non-implantable devices that deliver electrical, chemical or other agents to 
reversibly modify brain and nerve cell activity” [1]. These therapies are reversible and highly targeted 
to specific areas of the brain or spinal cord.  
 
Improved understanding of the neurocircuitry involved in eating disorders (EDs) and obesity [e.g. 2, 3, 
**4] has given rise to the use of neuromodulation and neurofeedback as illness probes and as emerging 
treatments [5]. In particular, researchers have implicated alterations in circuits involved in reward 
processing [6-9], affect, stress and negative valence [10, 11], appetite regulation [12, 13], and self-
regulatory control [6, 9]. To explain the extremes of behaviour across the spectrum of EDs (from severe 
food restriction/under-eating to overeating/binge eating), it has been proposed that these may result 
from a differentially altered balance between neural mechanisms of reward and inhibitory processing 
[9]. Neurobiological overlaps between EDs, obesity and addictions are being proposed [e.g. 14, 15, 16]. 
 
This review will focus on the most promising neuromodulation techniques, deep brain stimulation 
(DBS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation 
(tDCS), and neurofeedback [3, 17, 18]. We will describe these techniques and stimulation targets, 
describe potential underlying mechanisms and summarise recent findings in relation to the application 
of these techniques to clinical and sub-clinical eating and weight disorders and their impact on ED and 
other outcomes. Finally, we will consider acceptability, tolerability, safety and ethical considerations.  
 
Promising Neuromodulation Techniques and their Targets in Eating Disorders and Obesity 
Deep brain stimulation (DBS)  
This is a reversible neurosurgical intervention, whereby electrodes are implanted into a defined brain 
region and a battery-operated pulse generator (usually implanted in the chest) sends electrical pulses to 
the region to alter neural activity. Once implanted, the DBS device can be activated and programmed 
wirelessly, permitting real-time titration of stimulation parameters. Case studies of DBS to improve 
anorexia nervosa or comorbid symptoms (obsessive compulsive disorder, depression), targeting the 
nucleus accumbens, sub-genual cingulate cortex, ventral capsule/ventral striatum, or sub-callosal 
cingulate, have shown promise in highly selected severe and enduring cases [for review see 3, 18]. As 
yet, no RCTs have been carried out. Likewise in cases of severe obesity, hypothalamic or nucleus 
accumbens DBS has shown promise [for review see *19]. 
 
Non-invasive brain stimulation (NIBS) 
In transcranial magnetic stimulation (TMS) an electrical current is passed through a TMS coil, thus 
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generating a magnetic field. When the coil is held against the head, the field induces a secondary 
electrical current (i.e. activation of neurons) in the targeted brain region. Repetitive transcranial 
magnetic stimulation (rTMS) involves the delivery of multiple pulses over a short time period with 
effects that outlast the stimulation period (30–60 min). Low frequency rTMS (<5 Hz) is thought to 
suppress neural activity, but high frequency rTMS (>5 Hz) is thought to enhance activity [20].  
 
Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation. It involves 
the application of a low-intensity constant current (1–2mA) directly to the brain via scalp electrodes, 
which is thought to alter the electrical potential of neuronal membranes. Anodal (+ terminal) 
stimulation generally has cortical excitatory effects, whereas cathodal (– terminal) stimulation inhibits 
activity. Effects on cortical excitability can last beyond the stimulation period — up to 90 minutes. 
Long-term effects seem to operate through modifications of post-synaptic nerve connections, similar to 
long-term potentiation and long-term depression [20].  
 
Candidate targets for NIBS in EDs, based on a ‘Research Domain Criteria (RDoC) formulation’ of ED 
pathology have been described [**4]. These include targets in the cognitive control, positive and 
negative valences, and social processes systems. For pragmatic accessibility reasons, studies have 
targeted the dorso-lateral prefrontal cortex (DLPFC) or the dorso-medial prefrontal cortex (DMPFC) 
[**4, 21]. Several case studies, case series, and proof-of-concept RCTs of NIBS have shown promise in 
EDs, obesity and food craving [22-26]. 
 
Neurofeedback  
This form of biofeedback trains individuals to voluntarily regulate their brain activity in a target area in 
response to real time feedback [27]. The level of neural activity, as assessed via electroencephalography 
(EEG) or functional neuroimaging (fMRI), is fed back to the individual using a brain-computer 
interface and this provides continuously updated information about their success in regulating their 
neural activity [2, 17].  
 
Evidence Supporting Different Types of Neuromodulation and Neurofeedback in Eating 
Disorders and Obesity  
To provide an overview of recent clinical studies of invasive and non-invasive neuromodulation and 
neurofeedback in EDs and obesity, we systematically searched PubMed, Scopus, and Web of Science, 
using the following search terms: brain stimulation OR “TMS” OR transcranial magnetic stimulation 
OR “tDCS” OR “transcranial direct current stimulation” OR transcranial stimulation OR neurofeedback 
combined with food OR eating OR body OR anorexia OR anorexi* OR bulimia OR bulimi* OR obesity 
OR obes* OR binge eat*. We limited our search to articles in English published between October 2015 
and May 2017. We excluded studies where the focus was not on changes to eating behaviours or body 
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weight as a result of neuromodulation/neurofeedback (see Tables 1-3). 
 
To provide an overview of forthcoming but unpublished studies, we searched major national and 
international clinical trials registries, including the World Health Organization’s International Clinical 
Trials Registry, clinicaltrials.gov, ISRCTN registry, the Australian and New Zealand Clinical Trials 
Registry, ANZCTR, (using the above search terms individually). Details of these studies are presented 
in Table 4.  
 
DBS 
Our search identified one single case study of DBS in anorexia nervosa [28] and one open label trial of 
DBS, targeting the subcallosal cingulate cortex in 16 patients with chronic treatment-refractory anorexia 
nervosa [*29] (see Table 1). This was an extension of an earlier series of 6 patients [65] and is the 
largest series of DBS for anorexia nervosa. DBS treatment was associated with significant and sustained 
improvements in anxiety, depression and emotion regulation, and significant increases in body-mass 
index (BMI) at 12 months post-surgery [*29]. PET imaging showed significant changes in glucose 
metabolism in brain structures implicated in anorexia nervosa at 6 and 12 months follow-ups, compared 
with baseline, suggesting that DBS can directly affect anorexia-related brain circuitry. Two patients 
asked to have their device removed for poorly explained reasons. Ten out of 16 patients experienced at 
least one adverse event, however only one was thought to be DBS related (surgical site infection), most 
others were related to the underlying illness. A single case study of nucleus accumbens DBS in obesity 
was also identified [30].  
 
NIBS 
We identified 8 NIBS studies (n=232 participants), all targeting the DLPFC (see Table 2)  
 
Anorexia nervosa: 
Two studies assessed use of rTMS in anorexia nervosa. In a sham-controlled RCT, a single session of 
real rTMS, led to greater short-term reduction in ED symptoms and improved reward-related decision-
making (assessed through a temporal discounting paradigm) [*31]. In a subsequent case series, five 
adults with severe and enduring anorexia nervosa received 20 sessions of real rTMS [32]. This was 
associated with reductions in ED and affective symptoms. Improvements persisted up to 6 months post-
treatment but had waned by 12 months.  
 
Bulimia nervosa: 
Recent NIBS studies have shown mixed results in bulimia nervosa. A case series of single-session high-
frequency rTMS found reductions in food craving and hunger, but no change in ED symptoms [33]. 
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Likewise, a sham-controlled RCT of ten sessions of high-frequency rTMS in bulimia nervosa 
participants found no difference between groups in ED symptoms post-treatment [*34]. However, the 
study was limited, in that the stimulation target was not localised by neuronavigation and the number of 
rTMS sessions was relatively low. 
 
In contrast, a cross-over RCT using tDCS in bulimia nervosa, found that one session of anode 
right/cathode left active tDCS (but not anode left/cathode right active or sham tDCS) lead to 
improvements in cognitions and mood at post-treatment [*35]. Both active tDCS conditions suppressed 
the self-reported urge to binge-eat and increased self-regulatory control (assessed through temporal 
discounting paradigm). Group differences in frequency of ED symptoms were not observed 24-hours 
post-tDCS.  
 
Food craving, Binge Eating Disorder and Obesity: 
A study of healthy individuals with high food cravings, found active tDCS applied over 5 consecutive 
days significantly reduced food cravings in comparison to sham tDCS, both post-treatment and one 
month later [36].  
 
In a cross-over study, participants with binge eating disorder experienced reduced cravings for certain 
foods and consumed fewer calories following a single session of active tDCS, compared to sham tDCS 
[*37].  
 
Participants with obesity consumed fewer kilocalories/day from fat and soda and had a greater 
percentage weight loss, during active anodal tDCS treatment to the left DLPFC, compared to during 
cathodal tDCS [38]. There was no difference between sham and active groups in relation to weight 
change or food intake. 
 
Neurofeedback 
EEG neurofeedback has been investigated in two RCTs (see Table 3). Significant training effects were 
shown in eating behaviour, emotion regulation, and in some EEG parameters (although not as 
hypothesised) in a trial of EEG neurofeedback in adolescents with anorexia nervosa [*39]. Secondly, in 
participants with subthreshold binge eating disorder, 10 sessions of EEG neurofeedback (but not mental 
imagery and waitlist) reduced the frequency of binge eating post-treatment and at 3-months follow-up 
[*40]. 
Real-time fMRI neurofeedback has been assessed in one case series in individuals with obesity [*41]. In 
this proof-of-principle study, participants successfully managed to increase functional connectivity 
between the DLPFC and VMPFC, areas of the brain associated with executive control and reward 
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processing. Despite this, there was only a trend effect of neurofeedback training on food choice towards 
less high-calorie foods. 
 
Ongoing studies of neuromodulation and neurofeedback  
Details of 21 ongoing studies are presented in Table 4. The majority are trials of NIBS, with roughly 
equal numbers of rTMS and tDCS protocols. For both modalities, the majority of studies involve 
multiple sessions, targeting the prefrontal cortex. Additionally, there are five DBS studies in progress, 
three in anorexia nervosa and two in obesity. These trials will increase the evidence base for these 
procedures and help establish the validity of treatment protocols. 
 
 
An Emerging Scientific Rationale for the Use of Neuromodulation/ Neurofeedback  
It is beyond the scope of this paper to discuss extensively the evidence relating to different putative 
mechanisms of action underpinning different neuromodulation treatments. The interested reader may 
wish to consult the following reviews [e.g. 20, 66, 67]. Here, we briefly focus on two promising areas of 
investigation, the combination of neuroimaging and neuromodulation data, and secondly, the role of 
mechanisms related to memory reconsolidation. 
 
Neural correlates and predictors of change  
Studies combining neuroimaging and neuromodulation data are in their infancy in EDs. Such studies 
might be able to identify distinct neural endophenotypes, associated with differential intervention 
responses at the neural and the clinical level; they might also help tailor rTMS parameters to individual 
patients and they may shed light on illness mechanisms and strengthen the scientific rationale for the 
use of neuromodulation [68]. The first functional neuroimaging study in EDs patients undergoing NIBS 
involved 28 patients with longstanding binge-purge behaviours and failed previous treatments [68]. All 
received 20-30 sessions of 10 Hz DMPFC-rTMS. Based on a criterion of ≥ 50% reduction in weekly 
binge/purge frequency, participants were stratified into 16 treatment responders and 12 non-responders. 
There were widespread differences between the two groups in resting-state neural connectivity at 
baseline. Relative to non-responders, rTMS-responders showed baseline hypo-connectivity from the 
stimulation target to other cortical and subcortical regions. In responders, fronto-striatal connectivity 
was enhanced following DMPFC-rTMS, in association with reductions in binge-purge frequency. 
Conversely, in patients with higher baseline connectivity, DMPFC-rTMS had the opposite effect, 
reducing fronto-striatal connectivity, in association with worsening of or failure to improve symptoms. 
The need to conceptualise change in terms of neural networks in relation to neuromodulation in 
psychiatric disorders has been reviewed [**69].  
 
The role of learning and memory reconsolidation 
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As described, many studies emphasise the importance of motivational salience, reward and learned 
behaviours, and are consistent with neuromodulation that targets frontostriatal circuits. However, it is 
important to recognize the emerging role of learning in the development/maintenance of psychiatric 
illnesses, such as EDs, and the role of new learning in treatment [70, 71]. For this reason, it is 
appropriate to consider the neural underpinnings of memory as a potential neuromodulation target. Of 
particular clinical interest is reconsolidation, the process by which memories can be made labile via 
reactivation [e.g. 72, 73]. Reconsolidation is increasingly being used as a treatment target based on the 
assumption that psychological treatments are most effective when links between illness-relevant stimuli 
and maladaptive emotional, cognitive or behavioural responses are broken [e.g. 70]. This is the 
objective of exposure treatments [74, 75], however, an alternative approach is to update emotional 
memories by changing their salience during reconsolidation [76], using psychological or [e.g. 77, 78, 
79] pharmacological approaches [e.g. 80, 81-83]. Importantly, neuromodulation reportedly alters 
memory reconsolidation, and some studies have begun to assess the effects of tDCS on reconsolidation 
[84]. Mechanisms centre around the proposal that new memories arise when the balance between 
excitatory (glutamatergic) and inhibitory (GABA-ergic) (E-I) firing patterns are disrupted [61, 62], as 
can be promoted by neuromodulation. For example, tDCS has been shown to decrease GABA 
concentrations and hence may modulate the relationship between glutamate and GABAergic systems 
[61]. On the basis of such studies, our opinion is that molecular/physiological studies related to 
neuromodulation will need to identify which neurotransmitter systems are the main targets e.g. 5-HT (in 
relation to affect regulation), DA (in relation to reward and habits) and/or glutamate/GABA (E-I) (in 
relation to memory and synaptic plasticity). The importance of E-I systems in psychopathology and 
across psychiatric phenotypes has recently been discussed [e.g. 86] but, if explanatory models of 
neuromodulation increasingly centre around E-I systems, neuromodulation might be most effective as 
an adjunct to treatments involving memory reconsolidation. Lastly, the E-I balance and its relation to 
synaptic plasticity is an evolving subject and the complexity involved is likely to increase.  
 
Acceptability, Safety and Ethical Considerations 
In general, safety and acceptability of NIBS do not appear to be a problem [e.g. 87, 88, 89]. For 
example, a systematic review of tDCS studies found similarly low drop-out rates for real and sham 
tDCS [88]. However, these authors noted that the quality of adverse events reporting was low in most 
studies. Very limited research on this issue has been conducted in relation to EDs [90].  
 
Ethical considerations have mainly focused on DBS rather than on NIBS, given the invasiveness of 
DBS and its use in highly vulnerable, physically frail anorexia nervosa patients, whose capacity for 
making health-related decisions may be impaired. Additionally, families desperate to alleviate their 
loved one’s distress may push them towards agreeing to DBS. Other concerns have included the issue 
that DBS or NIBS might be perceived as ‘mind control’, increasing patients’ helplessness and reducing 
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their sense of authenticity [91, 92]. The limited literature exploring ED patients’ views shows that they 
are able to understand and reflect on issues related to gains and threats to their authenticity [93, 94]. In a 
case series (n=5) of therapeutic rTMS in anorexia nervosa, patients were asked about their experience 
[32]. They talked about greater cognitive clarity, flexibility and improved mood. There was no sense of 
altered authenticity or agency. Recently a neuro-ethics framework for the use of DBS in anorexia 
nervosa has been published [**95].  
 
Discussion 
During the last 20 months, seven case studies/series and seven RCTs of NIBS or neurofeedback in 
different EDs, obesity or food craving have appeared, with largely promising results. However, one 
NIBS trial, using a multi-session protocol in bulimia nervosa, was negative. A case series of sub-
callosal DBS in anorexia nervosa has also shown promise. A search of trial registries identified a further 
21 ED-focused neuromodulation/feedback studies in progress, suggesting that this is an area of growing 
interest. In parallel, safety, acceptability and ethical considerations are being systematically studied. 
Progress is also being made in relation to developing a rationale for use of neuromodulation treatments, 
substantially based on neural models of EDs/obesity, including the role of memory and its 
reconsolidation in their development and treatment. These advances together with the rapidly increasing 
knowledge of neural networks and their interconnectivity will lead to the formulation of new 
hypotheses on the aetiology and treatment of EDs. 
 
Whilst the evidence suggests that neuromodulation treatments have potential, as probes of illness 
mechanisms and as potential interventions in the treatment of EDs and obesity, much of this potential is 
still waiting to emerge. Much needs to be learnt about patient selection, intervention parameters, 
treatment targets and how to optimise protocols. Neurocognitive, neural and genetic predictors of 
outcome may help to individualise protocols and deliver personalised treatment.  
 
At present, the rationale for use of one NIBS procedure over another is unclear. Ultimately this may be 
mostly influenced by practical considerations such as costs, availability and commercial interests. In 
this respect, it is noted that portable tDCS devices are available, which can be used at home.  
 
Neuromodulation technologies continue to evolve, and for example, in the case of NIBS, are 
increasingly allowing more precise targeting of treatment, use of increasingly briefer and more powerful 
treatment protocols, probing deeper brain areas and stimulating multiple brain targets simultaneously 
[**4]. There is emerging evidence suggesting that these kinds of interventions may work synergistically 
when applied with different forms of cognitive training, as yet this combination treatment is unexplored 
in EDs. A framework for combining rTMS with behavioural interventions has been described [96]. 
Finally, another promising neurotechnology is fMRI neurofeedback, which as yet has not been explored 
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in relation to anorexia nervosa [17]. 
 
Conclusion 
At present neuromodulation and neurofeedback are largely experimental interventions; however, 
growing understanding of the mechanisms involved, together with the rising number of studies in this 
area means that the clinical utility of these interventions is likely to become clearer soon. 
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Table 1. Recent research studies of deep brain stimulation in weight and eating disorders. 
Author N Sample Treatment Type Design Area Protocol Findings Comments 
Anorexia Nervosa  
Blomstedt et 
al. (2017) 
[28] 
1 Adult female 
with chronic 
AN and 
severe MDD 
DBS Case study Bed nucleus of 
the stria 
terminalis 
(BNST) 
Bilateral 
stimulation of 
130 Hz, 120 μs 
pulse width, and 
4.3V (at 12 
months post-
surgery) to the 
BNST 
Food and eating-
related anxiety and 
obsessive thoughts 
vanished. Virtually 
stopped vomiting. 
Food intake more 
stable and less prone 
to large variations. 
No effect on BMI. 
Profound 
improvement in 
depression nine 
months post-surgery. 
Electrodes 
initially 
implanted in 
MFB, but due to 
side effects, 
stimulation was 
turned off. Re-
operated on for 
DBS of the 
BNST two years 
after first 
operation. 
Lipsman et 
al. (2017) 
[*29] 
16 Adults with 
enduring AN 
DBS Open-label trial Subcallosal 
cingulate 
Bilateral 
stimulation of 
130 Hz, 90 μs 
pulse width and 
5-6.5 V (at 12 
months post-
surgery) to the 
subcallosal 
cingulate  
Mean BMI increased 
significantly and, 
anxiety, depression 
and affective 
regulation improved 
over the 12 months 
post-surgery. 
 
Obesity 
Harat et al. 
(2016) [30] 
1 Adult female 
with 
hypothalamic 
obesity 
DBS Case study Nucleus 
accumbens 
Bilateral 
stimulation of 
208 μs pulse 
width, 130 Hz, 
and 3.75mA 
(final value) to 
the nucleus 
accumbens 
BMI decreased from 
52.9 pre-surgery to 
48.3 14 months post-
surgery, which was 
accompanied by 
improvement in the 
emotional state. 
 
N = number of participants; DSM = Diagnostic and Statistical Manual of Mental Disorders; AN = anorexia nervosa; MDD = major depressive disorder; DBS 
= deep brain stimulation; Hz = hertz; μs = microsecond; V = volts; BMI = body mass index; MFB = medial forebrain bundle 
 
 
 
  
Table 2. Recent research studies of NIBS in weight and eating disorders. 
Author N Sample Treatment Type Design Area Protocol Findings Comments 
Anorexia Nervosa 
McClelland 
et al. (2016) 
[*31] 
60 Adults with 
DSM-5 AN 
 
Right handed 
rTMS RCT 
 
Double-blind 
parallel group 
 
Conditions: 
(i) Real rTMS  
(ii) Sham rTMS 
Left DLPFC 
 
Neuronavigation 
20 × 5 s 
trains/55 s inter-
train interval at 
10 Hz = 1000 
pulses per 
session; 110% 
MT 
 
1 session 
In completers 
(n=49), core AN 
symptoms were 
significantly reduced 
post-rTMS and at 24-
hour follow-up in the 
real, but not sham, 
rTMS group. 
Proof-of-
concept trial 
McClelland 
et al. (2016) 
[32] 
5 Females with 
chronic 
treatment-
refractory 
DSM-5 AN 
 
Right handed 
rTMS Case series Left DLPFC 
 
Neuronavigation 
20 × 5 s 
trains/55 s inter-
train interval at 
10 Hz = 1000 
pulses per 
session; 110% 
MT 
 
~20 sessions 
From pre- to post-
treatment, ED and 
affective symptoms 
improved 
significantly and 
further 
improvements were 
seen at 6 months 
post-treatment. 
 
Bulimia Nervosa 
Sutoh et al. 
(2016) [33] 
8 Adults with 
DSM-IV-TR 
BN 
 
Right handed 
rTMS Case series Left DLPFC 
 
Located using 
5 cm anterior 
method 
20 × 5 s 
trains/55 s inter-
train interval at 
10 Hz = 1000 
pulses per 
session; 110% 
MT 
 
1 session 
At 4-hours post-
rTMS, a significant 
reduction in the 
subjective ratings of 
want to eat, urge to 
eat, and sense of 
hunger for high-
calorie food stimuli 
was found. No effect 
on eating disorder 
symptoms was 
identified. 
 
Gay et al. 
(2016) [*34] 
51 Females with 
DSM-IV BN 
 
Right handed 
rTMS RCT 
 
Double-blind 
parallel group 
 
Conditions: 
(i) Real rTMS 
(ii) Sham rTMS 
Left DLPFC 
 
Located using 
6 cm anterior 
method 
20 × 5 s 
trains/55 s inter-
train interval at 
10 Hz = 1000 
pulses per 
session; 110% 
MT 
 
10 sessions 
At post-treatment, no 
group differences in 
number of binges in 
15 days post-
treatment, features of 
binge episodes, 
number of days 
without bingeing, 
maximal craving 
before a binge, 
number of vomiting 
episodes and mood. 
 
Kekic et al. 
(2017) [*35] 
39 Adults with 
DSM-5 BN 
 
Right handed 
tDCS RCT 
 
Double-blind 
sham-controlled 
crossover 
 
Conditions:  
(i) Active tDCS: 
anode left / 
cathode right  
(ii) Active tDCS: 
anode right / 
cathode left  
(iii) Sham tDCS 
DLPFC 
 
Located using 
10–20 EEG 
system (F3 for 
left DLPFC and 
F4 for right 
DLPFC) 
2 mA; 20 
 minutes 
 
1 session per 
condition 
 
 
Anode right / 
cathode left active 
tDCS led to 
reductions in eating 
disorder cognitions 
and improvement in 
mood, compared to 
the other active and 
sham condition. Both 
active conditions 
suppressed the self-
reported urge to 
binge-eat. 
 
Frequent Food Cravings, Binge Eating Disorder, and Obesity 
Ljubisavljevi
c et al. 
(2016) [36] 
30 Healthy 
adults with 
high food 
cravings 
 
Right handed 
tDCS RCT 
 
Conditions: 
(i) Active tDCS: 
anode 
right/cathode left 
forehead 
(ii) Sham tDCS 
Right DLPFC 
 
Located using 
10–20 EEG 
system (F4 for 
right DLPFC) 
2 mA; 20 
 minutes 
 
5 sessions; 1 per 
day for 5 days 
 
 
Food cravings were 
significantly reduced 
by the end of 
treatment and at 30 
days post-treatment 
in the active, but not 
the sham, group. 
Sham group: 
Received real 
stimulation on 
1
st
 session 
Burgess et al. 
(2016) [*37] 
30 Adults with 
full or 
subthreshold 
(n=11) BED 
tDCS Single-blind 
sham-controlled 
crossover 
 
Conditions: 
(i) Active tDCS: 
anode right / 
cathode left  
(ii) Sham tDCS 
DLPFC 
 
Located using 
10–20 EEG 
system (F3 for 
left DLPFC and 
F4 for right 
DLPFC) 
2 mA; 20 
 minutes 
 
1 session per 
condition 
 
 
Active tDCS 
decreased craving 
more than sham for 
desserts, savoury 
proteins, and the all-
foods category. 
Participants ate less 
total kcals in the lab 
after active tDCS 
compared to 
following sham 
tDCS. 
Active tDCS 
reduced desire 
to binge-eat 5-6 
hours post-
tDCS, but only 
in male 
participants. 
Gluck et al. 
(2015) [38] 
9 Adults with 
obesity 
tDCS Double-blind, 
randomized, 
placebo-
controlled 
crossover 
 
Conditions:  
(i) Active tDCS: 
cathode left / 
anode left forearm 
(ii) Active tDCS: 
anode left / 
cathode above 
right eye 
(iii) Sham tDCS 
Left DLPFC 
 
Located using 
10–20 EEG 
system (F3 for 
left DLPFC) 
2mA; 40 
minutes 
 
3 sessions; 1 per 
day for 3 days  
Participants 
consumed 
significantly fewer 
kilocalories from 
soda and fat, and had 
a greater percentage 
weight loss during 
anodal compared to 
cathodal tDCS. No 
difference between 
sham and active 
groups for weight 
change or any food 
intake measure. 
All participants 
received 2 
treatment 
courses, 
maintaining 
original 
assignment to 
active and sham 
i.e. active group 
received both 
active tDCS 
montages, sham 
group received 
sham 
stimulation 
twice. 
 
N = number of participants; tDCS = transcranial direct current stimulation; rTMS = repetitive transcranial magnetic stimulation; EEG = 
electroencephalogram; DSM = Diagnostic and Statistical Manual of Mental Disorders; RCT = randomized controlled trial; mA = milliamps; Hz = hertz; MT 
= motor threshold; s = seconds; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; imaging; dlPFC = dorsolateral prefrontal cortex 
  
Table 3. Recent research studies of neurofeedback weight and eating disorders. 
Author N Sample Treatment Type Design Area Protocol Findings Comments 
Anorexia Nervosa 
Lackner et 
al. (2016) 
[*39] 
22 Female 
adolescents 
with DSM-5 
AN 
EEG 
Neurofeedback 
RCT 
 
Conditions: 
(i) Experimental: 
TAU plus 
Neurofeedback 
(EG) 
(ii) Control: TAU 
(CG) 
N/A Individual alpha 
frequency 
training  
 
10 sessions, 2 
per week for 5 
weeks 
 
At post-treatment, 
significant training 
effects were shown 
in eating behaviour, 
emotion regulation, 
and in some EEG 
parameters, although 
not as hypothesised.  
Rationale: alpha 
neurofeedback 
is supposed to 
be stress 
reducing. 
Binge Eating Disorder and Obesity 
Schmidt & 
Martin 
(2016) [*40] 
75 Adults with 
subthreshold 
BED 
EEG 
neurofeedback 
RCT 
 
Conditions: 
(i) EEG 
neurofeedback (ii) 
Mental Imagery 
(iii) Waitlist 
N/A Neurofeedback 
following food 
exposure 
 
10 sessions over 
6 weeks  
Only EEG 
neurofeedback led to 
a reduced frequency 
of binge eating. 
Distress associated 
with binge eating 
was reduced in both 
active conditions. 
The effects remained 
stable to a 3-month 
follow-up. 
 
Spetter et al. 
(2017) [*41] 
8 Male adults 
with obesity 
fMRI 
Neurofeedback 
Case series dlPFC and 
vmPFC 
Real-time fMRI 
neurofeedback; 
training to up-
regulate 
functional 
connectivity 
between the 
dlPFC and 
vmPFC 
 
Participants 
successfully learned 
to increase functional 
connectivity between 
dlPFC and vmPFC. 
No significant effect 
of training on food 
choice. 
 
6 sessions over 
4 weeks 
N = number of participants; DSM = Diagnostic and Statistical Manual of Mental Disorders; AN = anorexia nervosa; EEG = electroencephalogram; RCT = 
randomized controlled trial; TAU = treatment-as-usual; N/A = not applicable; BED = binge eating disorder; fMRI = functional magnetic resonance imaging; 
dlPFC = dorsolateral prefrontal cortex; vmPFC = ventromedial prefrontal cortex 
  
Table 4. Ongoing research studies of neuromodulation and neurofeedback treatments in EDs and obesity. 
 
Author(s), 
Year 
N Sample Inclusion criteria Design Protocol Primary Outcome 
DBS 
Aziz & Park 
(2013) [42] 
6 AN Females with DSM-IV 
AN, aged 20-65, illness 
duration > 7 years, 
treatment refractoriness 
according to pre-
specified criteria, BMI 
13-16 
Open label trial  
 
Safety/Efficacy 
Study 
DBS of the nucleus accumbens / 
anterior limb of internal capsule 
Adverse events associated with 
surgery or stimulation 13 month 
post-surgery, eating disorder 
pathology at 15 months assessed 
using the Eating Disorder 
Examination and the Yale 
Brown Eating Disorder Scale, 
BMI at 15 months 
Gao (2015) [43] 10 AN Adults with DSM-5 AN, 
age 18-65, BMI < 16, 
long-term 
pharmacotherapy 
resistance 
Single blind 
randomized 
parallel 
Continuous DBS of bilateral 
nucleus accumbens vs. Treatment 
with Fluoxetine 
BMI at 6 months 
Gorgulho et al. 
(2014) [44] 
6 Obesity Adults with obesity, 
aged 18-65, BMI > 40, 
failed diet, exercise, 
behaviour, and 
pharmacotherapy to 
control body weight 
Open label, 
feasibility trial 
DBS of the ventromedial 
hypothalamus 
Identification of possible 
adverse events after 12 months 
Luming & 
Fumin (2016) 
[45] 
16 AN Adults with DSM-5 
AN-R or AN-BP, aged 
20-60, chronicity or 
treatment resistance 
according to pre-
specified criteria 
Open label trial  
 
Safety/Efficacy 
Study 
DBS; target not reported Change from baseline in Eating 
Disorder Related Preoccupations 
and Rituals scores at 3 months, 6 
months and 12 months post-
surgery 
Rezai (2012) 
[46] 
3 Obesity Adults with obesity, 
aged 22-60, at least 24-
months post-gastric 
bypass surgery without 
evidence of a sustained 
Feasibility study DBS; target not reported Percentage of excess weight loss 
after 2 years 
improvement in BMI 
after gastric bypass 
surgery for at least 6 
months 
tDCS 
Choi (2015) 
[47] 
15 Obesity Adults with obesity, 
aged 20-80, BMI > 28 
Double-blind 
crossover 
 
 
1 session per condition 
 
2 mA; 20 minutes 
 
Real tDCS vs. Sham 
 
Anode: Right DLPFC, Cathode: 
Left DLPFC 
Regional brain activity 
measured by blood-oxygen-level 
dependent signal of functional 
MRI immediately after 
intervention 
Guillaume 
(2016) [48] 
10 AN Females with DSM-5 
AN, illness duration > 3 
years, aged 18-50, 
failure of at least one 
outpatient treatment 
conducted by a 
specialized team, BMI > 
13.5 
Open label 
treatment trial 
 
 
Pilot study 
20 sessions: twice a day for 2 
weeks 
 
2mA; 25 minutes 
 
Anode: Left DLPFC, Cathode: 
Right DLPFC 
Eating Disorder Examination - 
Questionnaire score at baseline 
and 1 month after last session of 
tDCS 
 
Mostafavi 
(2016) [49] 
50 Obesity Adults with overweight 
or obesity, aged 18-50, 
BMI > 25 
Single blind 
randomized 
parallel 
10 sessions 
 
2 mA; 20 minutes 
 
Real tDCS vs. Sham, both 
followed by a weight loss diet 
 
Target not reported 
Weight at baseline and after 2, 
6, and 8 weeks 
Piravej (2013) 
[50] 
64 Obesity Adults with overweight 
or obesity, aged 20-60, 
BMI > 25 
Randomized 
sham-controlled 
trial 
12 sessions: 3 sessions per week 
for 4 weeks 
 
2 mA; 20 minutes 
 
Real tDCS vs. Sham 
Visual analogue scales of 
"appetite" at baseline and 2 and 
4 weeks after intervention 
 Anode: Right DLPFC, Cathode: 
Left DLPFC  
Sandegani 
(2016) [51] 
20 Food 
craving 
Males with a food 
craving score at least 
one standard deviation 
higher than population 
mean, aged 18-70, BMI 
< 40 
Single blind 
randomized 
parallel 
1 session 
 
2 mA; 20 minutes 
 
Real tDCS vs. Sham 
 
Anode: Right DLPFC, Cathode: 
Left DLPFC  
Visual analogue scale of "food 
craving" at baseline, during and 
immediately after stimulation  
Vicari et al. 
(2015) [52] 
160 AN & 
BED 
Adolescents aged 13 to 
18, diagnosis of either 
DSM-5 AN (BMI below 
5th percentile) or BED 
with BMI > 85th 
percentile 
Double blind 
randomized 
parallel 
 
 
18 sessions: 3 times a week over 6 
weeks 
 
1mA; 20 minutes 
 
Real tDCS vs. Sham 
 
AN: Anode: Left DLPFC, 
Cathode: Right DLPFC  
 
BED: Anode: Right DLPFC, 
Cathode: Left DLPFC 
Proportion of patients in each 
treatment arm with change in > 
1 point of the total score of the 
Eating Disorder Inventory-3 
questionnaire at 6 weeks 
rTMS 
Avinoach et al. 
(2016) [53] 
60 Obesity Adults with obesity, 
aged 22-70, BMI 30-40, 
have had at least one 
prior conventional 
weight loss attempt, but 
no current weight loss 
attempts 
Single blind 
randomized 
parallel 
 
Number of sessions not reported. 
 
High frequency real deep TMS - 
right-to-left DLPFC vs. High 
frequency real deep TMS - left-to-
right DLPFC vs. Sham 
 
Target: DLPFC 
Change in weight between 
baseline, end of treatment (day 
15) and 1 month post-treatment 
Bartholdy et al. 
(2015) [54, 55] 
30 AN Adults with DSM-5 
AN-R or AN-BP, illness 
Randomized 
sham-controlled 
20 sessions: 5 days per week for 4 
weeks 
None defined as this is a 
feasibility trial. 
duration > 3 years, aged 
18 or over, BMI 14-
18.5, must have 
completed at least one 
adequate previous 
course of eating disorder 
treatment 
trial 
 
Feasibility trial 
 
High frequency real rTMS vs. 
Sham 
 
Target: Left DLPFC 
Chastan (2013) 
[56] 
54 AN Females with AN-R, 
aged 18-80, Illness 
duration 1-3 years, 
BMI<16 
Double blind 
randomized 
sham-controlled 
parallel 
10 sessions: in 2 weeks 
 
High frequency real rTMS vs. 
Sham 
 
Target: Inferior parietal cortex 
Body Shape Questionnaire 
(BSQ-34 scale) score 
immediately after rTMS 
Claudino et al. 
(2015) [57, 58] 
90 BED Females with DSM-5 
BED, aged 18-55, BMI 
> 35 
Double blind 
randomized 
sham-controlled 
parallel 
20 sessions: 3 sessions a week over 
approximately 7 weeks 
 
High frequency real rTMS vs. 
Sham 
 
Target: Left DLPFC 
Change in number of weekly 
binge eating episodes and 
craving between baseline and 2 
months 
Downar & 
Woodside 
(2016) [59] 
240 AN-BP 
or BN 
Adults with AN-BP or 
BN, aged 18-65, 
outpatient, failed to 
achieve clinical 
response to at least one 
pharmacological or 
behavioural treatment in 
current episode 
Randomized 
sham-controlled 
trial 
30 sessions: twice daily, 5 days per 
week for 3 weeks 
 
High frequency real rTMS (20 Hz) 
vs. Low frequency real rTMS (1 
Hz) vs. Sham 
 
Target: DMPFC 
Weekly BP frequency on Eating 
Disorder Examination at 
baseline, after each week of 
treatment, and 2, 6, and 12 
weeks post-treatment 
 
 
Ferrulli & Luzi 
(2015) [60] 
50 Obesity Adults with obesity, 
aged 22-65, BMI 30-45 
Double blind 
randomized 
sham-controlled 
parallel 
15 sessions: 3 days per week for 5 
weeks 
 
High frequency real deep TMS vs. 
Low frequency real deep TMS vs. 
Sham 
 
Target: PFC and insula 
Changes in food craving levels 
measured by the Food Cravings 
Questionnaire-Trait from 
baseline to end of treatment, and 
at 1 month, 6 months and 12 
months post-treatment 
Kim (2015) 
[61] 
60 Obesity Adults with overweight 
or obesity, aged 19-
65,BMI > 25 
Double blind 
randomized 
sham-controlled 
parallel 
4 sessions: 2 days per week 
 
High frequency real rTMS vs. 
Sham 
 
 Target: Left DLPFC 
Change in body weight 4-weeks 
post-treatment 
Nakazato 
(2014) [62] 
48 AN, BN 
& BED 
Adults with DSM-5 AN, 
BN or BED, aged 20-49, 
treatment resistant 
according to pre-
specified criteria 
Randomized 
sham-controlled 
trial 
 
Number of sessions not reported. 
 
High frequency real rTMS vs. 
Sham 
 
Target: Left DLPFC 
Change in visual analogue scale 
of "urge to eat" (administered 
before and after the rTMS 
sessions) 
Neurofeedback 
Hilbert & 
Blume (2016) 
[63] 
60 BED Adults with DSM-5 
BED with low 
frequency or low 
duration, aged 18-60, 
BMI 25-45 
Randomized 
controlled trial 
EEG Neurofeedback 
 
10 sessions: over 6 weeks 
 
Arm 1: Neurofeedback of specific 
EEG frequencies to reduce high 
beta activity and increase theta 
activity on electrode positions Cz, 
Fz, Fc1, and Fc2.  
 
Arm 2: Neurofeedback of the slow 
cortical potentials on EEG 
electrode position Cz.  
Number of binge-eating 
episodes at the end of treatment 
assessed using the Eating 
Disorder Examination 
Perchik & Cina 
(2015) [64] 
5 Obesity Males with obesity, 
aged 20-50, BMI 28-35 
Open label trial Hematoencephalography (HER) 
bio/neurofeedback using a HER 
and Near Infra-Red sensor. Based 
on differential oxygenated blood 
supply according to regional brain 
activity. 
Increase in brain activity in 
frontal brain areas after 7 weeks 
N = number of participants; tDCS = transcranial direct current stimulation; rTMS = repetitive transcranial magnetic stimulation; DBS = deep brain 
stimulation; EEG = electroencephalogram; DSM = Diagnostic and Statistical Manual of Mental Disorders; RCT = randomized controlled trial; mA = 
milliamps; Hz = hertz; MT = motor threshold; s = seconds; AN = anorexia nervosa; BN = bulimia nervosa; BED = binge eating disorder; imaging; dlPFC = 
dorsolateral prefrontal cortex; dmPFC= dorsomedial prefrontal cortex; PFC = prefrontal cortex; BMI = body mass index 
 
 
